<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572945</url>
  </required_header>
  <id_info>
    <org_study_id>Diabetic Foot in CKD patients</org_study_id>
    <nct_id>NCT04572945</nct_id>
  </id_info>
  <brief_title>Foot Abnormalities in Diabetic CKD Patients</brief_title>
  <official_title>Foot Abnormalities in Diabetic Patients With and Without Chronic Kidney Disease in Assuit University Hospitals; Case Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To find the correlation between different stages of CKD and type and severity of foot&#xD;
           abnormalities in diabetic patients with CKD.&#xD;
&#xD;
        2. To assess factors that may aggravate foot abnormalities in diabetic patients with CKD by&#xD;
           measuring serum calcium, phosphorus, parathyroid hormone, albumin, uric acid…etc.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease is an important contributor to morbidity and mortality, the global&#xD;
      prevalence of CKD was 9.1% (697.5 million cases) in 2017(1). Diabetes is a leading cause of&#xD;
      end stage renal disease worldwide. (2) Foot abnormalities and amputation are major health&#xD;
      concerns as they diminish health-related quality of life and cause financial burden (3).&#xD;
&#xD;
      KDIGO 2020 defines Chronic Kidney Disease (CKD) as persistently elevated urine albumin&#xD;
      excretion (≥30 mg/g [3mg/mmol] creatinine), persistently reduced estimated glomerular&#xD;
      filtration rate (eGFR &lt;60 ml/min per 1.73 m2), or both, for greater than 3 months. (4)&#xD;
      Diabetic foot is defined as either diabetic peripheral neuropathy, peripheral arterial&#xD;
      disease, infection, ulceration, or Charcot osteoarthropathy, or a combination of these&#xD;
      abnormalities, in a person diagnosed with diabetes mellitus, according to the guidelines of&#xD;
      International Working Group of Diabetic Foot 2020 (IWGDF). (5) There is a much higher&#xD;
      incidence of diabetic foot disorder in those with renal disease and outcomes are generally&#xD;
      poorer (2) as CKD patients are sharing three main risk factors of foot ulceration and&#xD;
      amputation: neuropathy, peripheral arterial disease and increased susceptibility to infection&#xD;
      with impaired wound healing. (6)&#xD;
&#xD;
      this research is conducted as little is known about the potential relationship between&#xD;
      chronic kidney disease and diabetic foot. This research evaluates the true burden of&#xD;
      different diabetic foot lesions in CKD patients, assesses the severity of diabetic foot in&#xD;
      different stages of CKD and the factors that may aggravate it in CKD, for future need to&#xD;
      modify our clinical policies in management of diabetic foot in CKD patients to provide better&#xD;
      prognosis and prevent long term disabilities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of foot abnormalities in diabetic CKD patient</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of foot abnormalities in diabetic CKD patient in different stages according to KIDGO 2012 classification</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">58</enrollment>
  <condition>CKD</condition>
  <condition>Diabetic Foot</condition>
  <arm_group>
    <arm_group_label>1- Cases: Diabetic patients with CKD.</arm_group_label>
    <description>classified according to estimated GFR into 5 stages according to KIDGO 2012 classification.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2- Controls: Diabetic patients without CKD.</arm_group_label>
    <description>defined as patients who have normal kidney function test, normal urine analysis and normal ultrasound findings.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>kidney function test</intervention_name>
    <description>laboratory and imaging</description>
    <arm_group_label>1- Cases: Diabetic patients with CKD.</arm_group_label>
    <arm_group_label>2- Controls: Diabetic patients without CKD.</arm_group_label>
    <other_name>HB A1c</other_name>
    <other_name>urine analysis</other_name>
    <other_name>abd us</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  The research includes patients recruited from Internal Medicine department Assiut&#xD;
             University Hospitals( renal and dialysis unit and diabetes and endocrinal center) ,&#xD;
             classified into two groups :&#xD;
&#xD;
               1. diabetic CKD patient (stage 1- stage 5 non D )&#xD;
&#xD;
               2. diabetic CKD patient (stage 5 D)&#xD;
&#xD;
          -  written or verbal consent should be taken from those patients that participate in the&#xD;
             study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diabetic CKD patients classified according to estimated GFR into 5 stages according to&#xD;
             KIDGO 2012 classification:&#xD;
&#xD;
             Stage 1 CKD: eGFR 90 or Greater Stage 2 CKD: eGFR Between 60 and 89 Stage 3 CKD: eGFR&#xD;
             Between 30 and 59 Stage 4 CKD: eGFR Between 15 and 29 Stage 5 CKD: eGFR Less than 15&#xD;
             etheir on dialysis ( satge 5 D) or not (stage 5 non D)&#xD;
&#xD;
          2. Age more than ≥18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients administer drugs causing neuropathy as:amiodarone, chemotherapy,&#xD;
             oxazolidinone linezolid, isoniazid, metronidazole, nitrofurantoin ,immunosuppressants,&#xD;
             nucleoside reverse transcriptase inhibitors, levodopa and antifungal drugs.&#xD;
&#xD;
          2. Patients with other causes of CKD.&#xD;
&#xD;
          3. Patients have other causes of PVD.&#xD;
&#xD;
          4. Age less than ˂18 years.&#xD;
&#xD;
          5. Patients' refusal to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>usra mo farrag, M.B.B.ch</last_name>
    <role>Principal Investigator</role>
    <affiliation>eygpt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Usra mo Farrag, M.B.B.ch</last_name>
    <phone>01013460518</phone>
    <email>usramohamed24@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Effat ab Toni, Prof.</last_name>
    <phone>01097330309</phone>
    <email>effattoni@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Carney EF. The impact of chronic kidney disease on global health. Nat Rev Nephrol. 2020 May;16(5):251. doi: 10.1038/s41581-020-0268-7.</citation>
    <PMID>32144399</PMID>
  </reference>
  <reference>
    <citation>Valabhji J. Foot problems in patients with diabetes and chronic kidney disease. J Ren Care. 2012 Feb;38 Suppl 1:99-108. doi: 10.1111/j.1755-6686.2012.00284.x.</citation>
    <PMID>22348369</PMID>
  </reference>
  <reference>
    <citation>Ndip A, Lavery LA, Boulton AJ. Diabetic foot disease in people with advanced nephropathy and those on renal dialysis. Curr Diab Rep. 2010 Aug;10(4):283-90. doi: 10.1007/s11892-010-0128-0. Review.</citation>
    <PMID>20532700</PMID>
  </reference>
  <reference>
    <citation>Hammond N, Wang Y, Dimachkie MM, Barohn RJ. Nutritional neuropathies. Neurol Clin. 2013 May;31(2):477-89. doi: 10.1016/j.ncl.2013.02.002. Review.</citation>
    <PMID>23642720</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>March 21, 2021</last_update_submitted>
  <last_update_submitted_qc>March 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Usra Mohamed Farrag Ahmed</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

